OTCMKTS:BLUSF BELLUS Health (BLUSF) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free BLUSF Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$6.46▼$14.5152-Week Range N/AVolume3.45 million shsAverage Volume39,610 shsMarket Capitalization$2.35 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get BELLUS Health alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About BELLUS Health Stock (OTCMKTS:BLUSF)BELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… BLUSF Stock News HeadlinesApril 15, 2024 | msn.comThis Viral Powder Blush Will Make You Give Up Your CreamsApril 13, 2024 | yahoo.comIf You Only Use 1 Blush for the Rest of Your Life, It Should Be This Powder-Cream DuoApril 25, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.November 8, 2023 | morningstar.comNatura &Co Holding SA ADR NTCOOctober 24, 2023 | health.usnews.comRaymond R. BlushJune 16, 2023 | benzinga.comBELLUS Health Inc. Announces Voting Results from Special Meeting of ShareholdersMay 12, 2023 | msn.comBELLUS Health: Q1 Earnings InsightsApril 19, 2023 | markets.businessinsider.comWhere BELLUS Health Stands With AnalystsApril 25, 2024 | Paradigm Press (Ad)Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.April 18, 2023 | msn.comGSK to Buy Bellus for $2 Billion to Gain Cough MedicineApril 5, 2023 | seekingalpha.comBellus Health posts proof-of-concept data for cough candidateApril 5, 2023 | markets.businessinsider.comBELLUS: Phase 1 Study Establishes Proof Of Concept For Developing ER Formulation Of CamlipixantApril 5, 2023 | markets.businessinsider.comBELLUS: Phase 1 Study Establishes Proof Of Concept For Developing ER Formulation Of CamlipixantNovember 14, 2022 | benzinga.comBELLUS Health Reports Third Quarter 2022 Financial Results and Business HighlightsNovember 14, 2022 | msn.comBellus Health (BLU) Reports Q3 Loss, Misses Revenue EstimatesOctober 10, 2022 | yahoo.comBELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual MeetingJuly 18, 2022 | benzinga.comBELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United StatesMarch 10, 2022 | gurufocus.comPower Corp of Canada Buys BELLUS Health Inc, Sells Alibaba Group Holding, New Oriental ...February 17, 2022 | gurufocus.comFirst Light Asset Management, LLC Buys AtriCure Inc, Keros Therapeutics Inc, BELLUS Health Inc, ...September 13, 2021 | benzinga.comWhat's Going On With BELLUS Health's Stock Today?See More Headlines Receive BLUSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2019Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:BLUSF CUSIPN/A CIKN/A Webwww.bellushealth.com Phone45-0680-4500FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,010,000.00 Net Margins-49,910.34% Pretax MarginN/A Return on Equity-48.37% Return on Assets-45.25% Debt Debt-to-Equity RatioN/A Current Ratio13.87 Quick Ratio13.87 Sales & Book Value Annual Sales$30,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / BookN/AMiscellaneous Outstanding Shares159,117,000Free FloatN/AMarket Cap$2.35 billion OptionableNot Optionable Beta1.55 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesRoberto BelliniPresident, Chief Executive Officer & DirectorFrançois DesjardinsVice President-FinanceDenis GarceauSenior Vice President-Drug DevelopmentTony MatzouranisVice President-Business DevelopmentSébastien RoySecretaryKey CompetitorsSTAAR SurgicalNASDAQ:STAATeladoc HealthNYSE:TDOCPatterson CompaniesNASDAQ:PDCOLifeStance Health GroupNASDAQ:LFSTArvinasNASDAQ:ARVNView All Competitors BLUSF Stock Analysis - Frequently Asked Questions How were BELLUS Health's earnings last quarter? BELLUS Health Inc (OTCMKTS:BLUSF) released its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01. The firm earned $0.01 million during the quarter. BELLUS Health had a negative net margin of 49,910.34% and a negative trailing twelve-month return on equity of 48.37%. This page (OTCMKTS:BLUSF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BELLUS Health Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
